Alpha Tau Medical Ltd.

NasdaqCM DRTS

Alpha Tau Medical Ltd. EBITDA for the year ending December 31, 2023: USD -28.03 M

Alpha Tau Medical Ltd. EBITDA is USD -28.03 M for the year ending December 31, 2023, a 14.40% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.

Alpha Tau Medical Ltd. EBITDA for the year ending December 31, 2022 was USD -32.74 M, a -147.76% change year over year.
Alpha Tau Medical Ltd. EBITDA for the year ending December 31, 2021 was USD -13.21 M, a -44.30% change year over year.
Alpha Tau Medical Ltd. EBITDA for the year ending December 31, 2020 was USD -9.16 M, a -15.28% change year over year.
Alpha Tau Medical Ltd. EBITDA for the year ending December 31, 2019 was USD -7.94 M.

Key data

Date	EBITDA	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)

NasdaqCM: DRTS

Alpha Tau Medical Ltd.

CEO	Mr. Uzi Sofer
IPO Date	March 8, 2021
Location	Israel
Headquarters	5 Kiryat Hamada Street
Employees	121
Sector	Health Care
Industries Clinical Trials Biotechnology Pharmaceuticals

Description

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.

Key trends

Past 5 years